Minnetronix’ optical systems expertise and manufacturing capabilities helped Oculogica quickly scale production to launch the EyeBOX® this month
SAINT PAUL, MINN. (March 8, 2022) – Minnetronix Medical announced it was selected as the medical device technology partner for the Oculogica EyeBOX®, a medical device used as an aid in diagnosing concussion. Minnetronix was chosen by Oculogica for its complex optical systems knowledge, integrated optical manufacturing and line testing capabilities, and strategic supply chain management experience.
EyeBOX® uses ocular motility and other domains of brain function to detect concussion. It is the only FDA-cleared objective diagnostic based on cranial nerve function and its relation to eye movement. Minnetronix provided Oculogica with a streamlined production transfer process that reduced risks and accelerated time to market.
Within Minnetronix’ dedicated New Production Introduction space designed to accelerate manufacturing startups, the team quickly developed, qualified, and scaled manufacturing of the device from early phase builds through commercial production, supporting a fast-tracked timeline from manufacturing transfer in fall of 2021 to launching commercially available products in February 2022, shortly after EyeBOX® obtained FDA clearance.
Minnetronix’ holistic approach also included creative solutions to overcome supply chain challenges, such as recommending a unique development solution aimed at optimizing unit cost and component availability for the circuit boards used in the device.
“We took the process development, engineering, manufacturing, and supply chain burden off Oculogica so they could focus on the big picture of preparing to launch and commercialize the EyeBOX® and grow their business,” said Matt Adams, vice president and general manager at Minnetronix. “Our comprehensive approach and deep optical systems expertise made us best positioned to help Oculogica accelerate its path to market under tight deadlines.”
“Their experience with complex optical systems, manufacturing capabilities, and focus on innovation made Minnetronix a natural fit for us,” said Rosina Samadani, PhD, CEO of Oculogica. “This partnership enabled us to bring our latest technology to market quickly and efficiently.”
The Minnetronix work on the EyeBOX® comes on the heels of its recent partnership announcement with optics research firm INO, further solidifying Minnetronix’ commitment to expanding its ability to innovate and accelerate optics and photonics-based medical devices to market.
“We’ve seen tremendous growth in optics projects as our expertise in this specialty continues to deepen,” said Adams.
About Minnetronix Medical
Since 1996, Minnetronix Medical has accelerated medical device breakthroughs as a design, development, and manufacturing partner to leading device companies around the world. Today, through lifecycle efficiency, opportunity realization, and increased utility, the company creates value in key technology segments that include RF energy, fluid and gas management, optical systems, and stimulation and active wearables. From design and manufacturing services to whole product solutions, Minnetronix has the expansive industry insight and intentional technical acumen to deliver better medical devices to market, faster. More information can be found on the Minnetronix website, by calling 651-917-4060 or emailing info@minnetronixneuro.com.